Clinical Trials

Phase 1/2 Active not recruiting

Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03277729 2026-01-05

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

53 enrolled 11 charts

Phase 1/2 Not yet recruiting

Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07020260 2025-06-13

PACMAN

18 enrolled

Burkitt Lymphoma, Leukemia, Lymphoma

NCT03467256 2023-02-24

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

18 enrolled

Other hematologic neoplasmPlasma cell

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04097301 2022-01-19

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Phase 1/2 Terminated

8 enrolled 13 charts

Multiple Myeloma, Leukemia, Myeloid, Acute

NCT04790747 2021-03-10

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Other hematologic neoplasm

50 enrolled

Recurrence, Hematologic Neoplasms

NCT04206943 2020-01-27

ISIKOK-19

24 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

73 enrolled

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

NCT02965092 2019-05-10

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

80 enrolled

Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02819583 2016-10-25

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT02851589 2016-08-01

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT02315118 2016-06-22

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

18 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01864902 2016-01-28

CART33